ZLDPF Zealand Pharma A/S

Zealand Pharma conference call on November 13 at 2pm CET (8am ET) to present third quarter 2025 financial results

Zealand Pharma conference call on November 13 at 2pm CET (8am ET) to present third quarter 2025 financial results

Press Release – No. 15 / 2025

Zealand Pharma conference call on November 13 at 2pm CET (8am ET) to present third quarter 2025 financial results

Copenhagen, Denmark, November 6, 2025 – Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, announced that it will host a conference call on November 13, 2025, at 2:00 pm CET (8:00 am ET) following the announcement of financial results for the third quarter of 2025.

Participating in the call will be President and Chief Executive Officer, Adam Steensberg; Chief Financial Officer, Henriette Wennicke; and Chief Medical Officer, David Kendall. The presentation will be followed by a Q&A session.

To receive telephone dial-in information and a unique personal access PIN, please register at . The live listen-only audio webcast of the call and accompanying slides presentation will be accessible at .  Participants are advised to register for the call or webcast approximately 10 minutes before the start. A recording of the event will be available following the call on the Investor section of Zealand Pharma’s website at .

About Zealand Pharma A/S

Zealand Pharma A/S (Nasdaq: ZEAL) is a biotechnology company focused on the discovery and development of peptide-based medicines. More than 10 drug candidates invented by Zealand Pharma have advanced into clinical development, of which two have reached the market and three candidates are in late-stage development. The company has development partnerships with a number of pharma companies as well as commercial partnerships for its marketed products.

Zealand Pharma was founded in 1998 and is headquartered in Copenhagen, Denmark, with a presence in the U.S. For more information about Zealand Pharma’s business and activities, please visit .

Contacts

Adam Lange (Investors)

Vice President, Investor Relations

Neshat Ahmadi (Investors)

Investor Relations Manager

Rachel James-Owens (Media)

Vice President, Corporate Communications & Media Relations

Zealand Pharma

Email:



EN
06/11/2025

Underlying

ZLDPFZealand Pharma A/S

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Zealand Pharma A/S

Mathijs Geerts Danau
  • Mathijs Geerts Danau
ZLDPF Zealand Pharma ...

Zealand Pharma Uneventful 3Q25 results, upcoming CMD in December 2025

Zealand reported 3Q25 results and provides a business update which are in line with expectations. We note that dapiglutide development has been paused but that most important timelines have been reiterated. For the remainder or this year we do not expect big readouts, but look forward to the CMD in December. DKK 1,120 TP and BUY rating reiterated.

ZLDPF ZEALAND PHARMA A/S
17h / 51m 17h / 51m 1 EN
Guy Sips ... (+7)
  • Guy Sips
  • Hilde Van Boxstael
  • Jacob Mekhael
  • Mathijs Geerts Danau
  • Thomas Couvreur
  • Wim Hoste
  • Wim Lewi
SOLB SOLVAY SA
AGFB AGFA-GEVAERT NV ... (+10)

Morning Notes : AGN NA, AGFB BB, IVA FP, MDXH BB, MELE BB, SOLB BB, DE...

: AGN NA, AGFB BB, IVA FP, MDXH BB, MELE BB, SOLB BB, DEME BB, AUTL US, ZEAL DC, PHVS US

SOLB SOLVAY SA
AGFB AGFA-GEVAERT NV
ZLDPF ZEALAND PHARMA A/S
MELE MELEXIS NV
IVA INVENTIVA SA
AUTL AUTOLUS THERAPEUTICS ADS
PHVS PHARVARIS NV
DEME DEME GROUP NV
AGN AEGON N.V.
MDXH MDXHEALTH
17h / 58m 17h / 58m 1 EN
 PRESS RELEASE
Free
ZLDPF Zealand Pharma ...

Zealand Pharma Announces Financial Results for the First Nine Months o...

Zealand Pharma Announces Financial Results for the First Nine Months of 2025 Company announcement – No. 23 / 2025 Zealand Pharma Announces Financial Results for the First Nine Months of 2025With petrelintide advancing at full speed and topline data rapidly approaching for both petrelintide and survodutide, upcoming Capital Markets Day will set the stage for a catalyst-rich 2026. Achieved key milestone in the petrelintide Phase 2 ZUPREME-1 trial in people with overweight and obesity, with the last participant completing the 28-week primary endpoint visit, paving the way for 42-week topline...

19h / 55m 1 EN
 PRESS RELEASE
Free
ZLDPF Zealand Pharma ...

Zealand Pharma to participate in the Jefferies Global Healthcare Confe...

Zealand Pharma to participate in the Jefferies Global Healthcare Conference Press release – No. 16 / 2025 Zealand Pharma to participate in the Jefferies Global Healthcare Conference Copenhagen, Denmark, November 12, 2025 - Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, announced that Chief Executive Officer, Adam Steensberg, will participate in a fireside chat at the Jefferies Global Healthcare Conference in London at 10:30am GMT (11:30am CET) on Wednesday, November 19, 2025. A ...

November 12, 2025 1 EN
 PRESS RELEASE
Free
ZLDPF Zealand Pharma ...

Zealand Pharma conference call on November 13 at 2pm CET (8am ET) to p...

Zealand Pharma conference call on November 13 at 2pm CET (8am ET) to present third quarter 2025 financial results Press Release – No. 15 / 2025 Zealand Pharma conference call on November 13 at 2pm CET (8am ET) to present third quarter 2025 financial results Copenhagen, Denmark, November 6, 2025 – Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, announced that it will host a conference call on November 13, 2025, at 2:00 pm CET (8:00 am ET) following the announcement of fi...

November 6, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch